时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
Liver disease is a leading cause of morbidity and premature mortality, contributing to an estimated two million deaths each year globally [].；Hepatitis C virus (HCV) can lead to progressive liver damage, resulting in cirrhosis and associated complications [].
方法
ETHOS Engage is an observational cohort study.；Participants were enrolled across three recruitment waves.；During Wave 1 (May 2018–September 2019) recruitment occurred in 25 sites, including drug treatment clinics (n = 21) and needle and syringe programs (NSPs) (n = 4).；During Wave 2 (November 2019–June 2021), recruitment occurred in 21 of the 25 sites which participated in Wave 1, including drug treatment clinics (n = 19) and NSPs (n = 2).
核心结论
Among individuals with valid LSM and ever eligible for HCV treatment (HCV RNA detectable or ever received treatment), 72% (1106/1525) self‐reported history of HCV treatment.；Treatment coverage increased from 64% (448/696) in Wave 1, to 71% (285/398) in Wave 2, and 87% (373/431) in Wave 3.；Among participants with a valid LSM (n = 3093), 43.4% were < 5 kPa, 48.9% 5–9.9 kPa, 5.2% 10–14.9 kPa, 1.5% 15–19.9 kPa, 0.6% 20–24.9 kPa, and 1.5% kPa ≥ 25, indicative of clinically significant portal hypertension and high risk of end‐stage liver disease complications (Figure ). ‖ 结论：In conclusion, this study demonstrates declining advanced liver disease among people who inject drugs in the era of DAA therapies for HCV.
局限
A potential explanation is confounding, due to the absence of variables such as BMI and liver steatosis.；The lower risk of advanced chronic liver disease among those with more recent injecting drug use emphasizes the crucial role of BMI assessment and CAP score to investigate potential confounding.；There were several limitations to this study.
对本项目的价值
★☆☆☆☆ 代谢轴既干预敏感性最高，也是老药新用供给最充足的来源。
全文来源
PMC JATS 全文（正文 24,447 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Reductions in Advanced Chronic Liver Disease Among People Who Inject Drugs: The ETHOS Engage Study.
- 期刊与标识：Liver Int · PMID 42958891 · DOI 10.1111/liv.70940
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。